Clinical Trials List
2022-10-01 - 2027-12-31
Phase III
Not yet recruiting2
Recruiting9
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- KUAN-RAU CHIOU 無
- I-jen Chiu 無
- Li-Yee Hong 無
- YUNG-HO HSU 無
- Cai-Mei Zheng 無
- Mei-Yi Wu 無
- Chia-Te Liao 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 朱志生 無
- 吳韋璁 無
- Ye-Hsu Lu 無
- 顏學偉 無
- WEN-TER Lai 無
- Chun-Yuan Chu 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 方燕楠 無
- 鍾文榮 無
- Huang-Chung Chen 無
- Po-Jui Wu 無
- 劉文浩 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chien-Yi Hsu 無
- 詹超舜 無
- Tsung-Lin Yang 無
- 陳志維 無
- 蕭成儀 無
- 鄭宇倫 無
- Yung-Ta Kao 無
- 蕭卜源 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tse-Min Lu 無
- Tze-Fan Chao 無
- 李慶威 無
- Chern-En Chiang
- Hao-min Cheng 無
- 黃偉銘 無
- 蔡依霖 無
- 黃少嵩 無
- 郭泠 無
- Wen-Chung Yu 無
- 吳承學 無
- 張俊欽 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
‧ Death from all causes
‧ Non-fatal myocardial infarction (MI)
‧ Non-fatal stroke
‧ Coronary artery revascularization, or
‧ Heart failure events leading to hospitalization or emergency medical attention
Inclution Criteria
Are either
individuals ≥40 years of age with established cardiovascular disease (CVD).
CVD is defined as meeting at least one of the following:
Coronary artery disease
Cerebrovascular disease
Peripheral arterial disease OR
individuals without established CVD but have the presence of cardiovascular (CV) risk factors (primary prevention)
women 55-69 years of age or men 50-64 years of age with at least 3 risk factors like tobacco use, dyslipidemia, hypertension at screening, or
women ≥70 years of age or men, ≥65 years of age with at least 2 risk factors at screening.
Exclusion Criteria
Have type 1 diabetes (T1D) or (T2D), history of ketoacidosis, or hyperosmolar state/coma
Have laboratory evidence diagnostic of diabetes mellitus at screening of HbA1c ≥6.5% (≥48 millimole/mole (mmol/mol) or fasting glucose (FG) ≥126 milligram/deciliter (≥7.0 millimole/liter (mmol/L).
Any one of the following CV conditions within 90 days prior to screening
MI
acute coronary syndrome
stroke
coronary or peripheral arterial revascularization procedure, which may also include carotid artery revascularization, or
acute decompensated heart failure
Have a known clinically significant gastric emptying abnormality such as severe gastroparesis or gastric outlet obstruction or have undergone or currently planning any gastric bypass (metabolic) surgery or restrictive bariatric surgery. Note: Liposuction or abdominoplasty are not considered as gastric bypass procedures.
Have a history of chronic or acute pancreatitis
Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Have acute or chronic hepatitis, or clinical signs or symptoms of any other liver disease, or have elevated liver enzyme measurements, determined by the central laboratory at screening
Have a presence or history of malignant neoplasms within the past 5 years prior to screening.
The Estimated Number of Participants
-
Taiwan
320 participants
-
Global
15000 participants
